NCT01598051View on ClinicalTrials.gov

Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

741

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 9, 2016

Study Completion Date

March 31, 2017

Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG

Rivaroxaban (Xarelto_ BAY59-7939)

Patients treated with Xarelto under practical manner for SPAF.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT01598051 - Xarelto [SPAF-QOL] Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter